2022
DOI: 10.20944/preprints202204.0060.v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Time-Limited Therapy With Belatacept in Kidney Transplant Recipients

Abstract: In kidney transplant recipients, belatacept is usually pursued indefinitely after it has been started. In the setting of the belatacept shortage and after having evaluated the benefit-risk ratio, we established a strategy consisting of time-limited belatacept therapy / transient calcineurin inhibitor withdrawal, whose results are analyzed in that study. We considered all the kidney transplant recipients that had been switched from conventional immunosuppressive therapy to belatacept and then for whom belatacep… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 33 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?